H.A. Burris

927 total citations
63 papers, 679 citations indexed

About

H.A. Burris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, H.A. Burris has authored 63 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in H.A. Burris's work include Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (18 papers) and Advanced Breast Cancer Therapies (14 papers). H.A. Burris is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (18 papers) and Advanced Breast Cancer Therapies (14 papers). H.A. Burris collaborates with scholars based in United States, Switzerland and United Kingdom. H.A. Burris's co-authors include Daniel D. Von Hoff, John G. Kuhn, Martha H. Marshall, Axel‐R. Hanauske, Susan G. Hilsenbeck, Randall K. Johnson, M.L. Rothenberg, John D. Hainsworth, José Baselga and Suzanne F. Jones and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

H.A. Burris

60 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.A. Burris United States 13 496 316 213 111 72 63 679
P.N. Munster United States 12 336 0.7× 307 1.0× 119 0.6× 49 0.4× 79 1.1× 18 584
Aruna Mani United States 15 725 1.5× 202 0.6× 267 1.3× 218 2.0× 145 2.0× 28 982
Véronique Cabaret France 9 392 0.8× 158 0.5× 90 0.4× 229 2.1× 72 1.0× 20 588
Brent O’Carrigan United Kingdom 8 514 1.0× 425 1.3× 117 0.5× 64 0.6× 95 1.3× 17 759
Oriol Arpí Spain 15 376 0.8× 359 1.1× 126 0.6× 64 0.6× 149 2.1× 24 710
Peter L. Depowski United States 9 301 0.6× 319 1.0× 88 0.4× 75 0.7× 94 1.3× 15 538
Mélanie Desbois France 8 560 1.1× 310 1.0× 149 0.7× 25 0.2× 134 1.9× 16 912
Sandra Tomek Austria 11 263 0.5× 243 0.8× 189 0.9× 171 1.5× 113 1.6× 17 599
Kristine Rinn United States 11 541 1.1× 281 0.9× 91 0.4× 383 3.5× 104 1.4× 23 997
Stephen Castaneda United States 10 356 0.7× 217 0.7× 143 0.7× 76 0.7× 83 1.2× 14 685

Countries citing papers authored by H.A. Burris

Since Specialization
Citations

This map shows the geographic impact of H.A. Burris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.A. Burris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.A. Burris more than expected).

Fields of papers citing papers by H.A. Burris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.A. Burris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.A. Burris. The network helps show where H.A. Burris may publish in the future.

Co-authorship network of co-authors of H.A. Burris

This figure shows the co-authorship network connecting the top 25 collaborators of H.A. Burris. A scholar is included among the top collaborators of H.A. Burris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.A. Burris. H.A. Burris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schüler, Martin, Donald A. Berry, H.A. Burris, et al.. (2024). Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial. FreiDok plus (Universitätsbibliothek Freiburg). 1 indexed citations
2.
3.
4.
Han, Heon, Lajos Pusztai, Sara A. Hurvitz, et al.. (2021). 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Annals of Oncology. 32. S474–S475. 23 indexed citations
5.
6.
Burris, H.A., Michael Gnant, G. N. Hortobágyi, et al.. (2013). Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. Cancer Research. 73(24_Supplement). P2–16. 2 indexed citations
7.
Burris, H.A., J. Thaddeus Beck, Hope S. Rugo, et al.. (2012). Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy. Annals of Oncology. 23. ix121–ix122. 1 indexed citations
8.
Rugo, H. S., K.I. Pritchard, Michael Gnant, et al.. (2012). 253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. European Journal of Cancer. 48. S116–S116. 8 indexed citations
9.
Diéras, V., Nadia Harbeck, Kathy S. Albain, et al.. (2010). Abstract P3-14-01: A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results. Cancer Research. 70(24_Supplement). P3–14. 34 indexed citations
10.
Burris, H.A., S. Vukelja, Ian E. Krop, et al.. (2009). 5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results. European Journal of Cancer Supplements. 7(2). 266–267. 1 indexed citations
11.
Cabell, Christopher H., Susan E. Bates, Richard Piekarz, et al.. (2009). Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Journal of Clinical Oncology. 27(15_suppl). e19533–e19533. 9 indexed citations
12.
Meluch, Anthony A., H.A. Burris, Cassie M. Lane, et al.. (2009). Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. Journal of Clinical Oncology. 27(15_suppl). 6012–6012. 9 indexed citations
13.
Spigel, David R., John D. Hainsworth, Denise A. Yardley, et al.. (2006). Preoperative gemcitabine (G) and docetaxel (D) in patients (pts) with stage IB, II, or III non-small cell lung cancer (NSCLC): A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 17007–17007. 1 indexed citations
14.
Tabernero, Josep, Federico Rojo, H.A. Burris, et al.. (2005). A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3007–3007. 53 indexed citations
15.
16.
Burris, H.A.. (2001). Docetaxel (taxotere) plus trastuzumab (herceptin) in breast cancer. Seminars in Oncology. 28(1D). 38–44. 36 indexed citations
17.
Peacock, N. W., H.A. Burris, Véronique Dièras, et al.. (1998). A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Investigational New Drugs. 16(1). 37–43. 5 indexed citations
18.
Burris, H.A., et al.. (1995). Docetaxel (Taxotere) in combination: a step forward.. PubMed. 22(6 Suppl 13). 35–40. 12 indexed citations
19.
Burris, H.A.. (1994). Preclinical Pharmacology and Phase I Clinical Trials. Annals of Pharmacotherapy. 28(5_suppl). S7–S10. 4 indexed citations
20.
Burris, H.A., Axel‐R. Hanauske, Randall K. Johnson, et al.. (1992). Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro. JNCI Journal of the National Cancer Institute. 84(23). 1816–1820. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P.N. Munster Breakdown of academic impact, for papers by Aruna Mani Breakdown of academic impact, for papers by Véronique Cabaret Breakdown of academic impact, for papers by Brent O’Carrigan Breakdown of academic impact, for papers by Oriol Arpí Breakdown of academic impact, for papers by Peter L. Depowski Breakdown of academic impact, for papers by Mélanie Desbois Breakdown of academic impact, for papers by Sandra Tomek Breakdown of academic impact, for papers by Kristine Rinn Breakdown of academic impact, for papers by Stephen Castaneda
Rankless by CCL
2026